NASDAQ:VRDN Viridian Therapeutics Q4 2024 Earnings Results & Report $30.85 -0.40 (-1.29%) As of 11:23 AM Eastern This is a fair market value price provided by Massive. Learn more. Viridian Therapeutics beat analyst expectations on both earnings and revenue in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$0.81 versus the -$1.05 consensus estimate, while revenue of $72 thousand topped the $49 thousand estimate by $23.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 27, 2025TimeBefore Market OpensConference Call7:00 AM ET Viridian Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$1.05Beat/MissBeat by +$0.24One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersViridian Therapeutics Revenue ResultsActual Revenue$72 thousandExpected Revenue$49 thousandBeat/MissBeat by +$23.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Viridian Therapeutics Q4 2024 Earnings FAQ Did Viridian Therapeutics beat earnings estimates for Q4 2024? Viridian Therapeutics (NASDAQ:VRDN) reported earnings of -$0.81 per share for Q4 2024, beating the consensus estimate of -$1.05. The report was announced on Thursday, February 27, 2025. What was Viridian Therapeutics' revenue for Q4 2024? Viridian Therapeutics reported revenue of $72 thousand for Q4 2024, against a consensus estimate of $49 thousand. Viridian Therapeutics Earnings HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Editas Medicine (EDIT) and Praxis Precision Medicines (PRAX)November 12 at 3:39 AM | theglobeandmail.comViridian Therapeutics: FcRn Pipeline Takes Shape After VRDN-008 Phase 1 ResultsNovember 10 at 9:30 PM | seekingalpha.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 12 at 1:00 AM | Weiss Ratings (Ad)Wedbush Adjusts Price Target on Viridian Therapeutics to $44 From $42, Maintains Outperform RatingNovember 9 at 6:23 PM | marketscreener.comMViridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies saysNovember 9 at 6:23 PM | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans TranscriptNovember 9 at 3:00 PM | seekingalpha.comSee More Viridian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email. Email Address About Viridian TherapeuticsViridian Therapeutics (NASDAQ:VRDN) is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration. These candidates remain investigational. Viridian’s roots include Miragen Therapeutics, which adopted the Viridian Therapeutics name in 2021. The company conducts clinical development to evaluate its potential treatments; its candidates are not approved medicines.View Viridian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
